Dr. Laube’s research involves in vivo and in vitro quantification of the deposition and removal of particles in healthy and diseased lungs and noses using radiolabeled aerosols and scintigraphic imaging assessments.
Computer analyses of the scintigraphic images provide improved methods for assessing the efficacy of a variety of inhaled medications that are administered to the lung or nose. This approach is very useful in the development of aerosol therapies for treating asthma and cystic fibrosis and for answering basic physiologic questions about mucociliary clearance, a major lung defense mechanism.
Laube BL, Sharpless G, Vikani AR, Harrand V, Zinreich SJ, Sedberry K, Knaus D, Barry J, Papania M. "Intranasal Deposition of Accuspray™ Aerosol in Anatomically Correct Models of 2-, 5-, and 12-Year-Old Children." J Aerosol Med Pulm Drug Deliv. 2015 Feb 13. [Epub ahead of print]
Laube BL. "The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination." Respir Care. 2005 Sep;50(9):1161-76.
Garvey C, Fahy B, Lareau S, Braman S, Laube B. "Using your metered dose inhaler (MDI)." Am J Respir Crit Care Med. 2014 Oct 15;190(8):P5-6. doi: 10.1164/rccm.1908P5.
Lin WH, Pan CH, Adams RJ, Laube BL, Griffin DE. "Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA." MBio. 2014 Apr 15;5(2):e01047. doi: 10.1128/mBio.01047-14.
Laube BL, Sharpless G, Benson J, Carson KA, Mogayzel PJ Jr. "Mucus removal is impaired in children with cystic fibrosis who have been infected by Pseudomonas aeruginosa." J Pediatr. 2014 Apr;164(4):839-45. doi: 10.1016/j.jpeds.2013.11.031. Epub 2013 Dec 24.